YVES POMMIER

Company: National Cancer Institute

Job title: Chief, Developmental Therapeutics Branch, Center for Cancer Research

Seminars:

Exploring Schlafen 11 as a Cellular Determinant of Response to TOP1 Inhibitor Payloads, Including Non-Campothecin and Synergistic Drug Combinations 9:45 am

Establishing the molecular mechanism of action of TOP1 poisons and potential synergistic drug combinations with TOP1 poisons Emphasizing the importance of using Schlafen 11 (SLFN11) as determinant of response to TOP1 inhibitor payloads Showcasing non-camptothecin TOP1 inhibitors as improved options for TOP1 payloadsRead more

day: Conference Day One